Skip to main content
Log in

Metastasis in Soft Tissue Sarcomas: Prognostic Criteria and Treatment Perspectives

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Soft tissue sarcomas (STSs) are rare tumors, notorious for early hematogenous metastasizing. Metastatic disease is seldom amenable to curative treatment; therefore new treatment modalities are required. Treatment-related and tumor-related prognostic factors can be assessed to estimate the risk for subsequent metastases, as will be discussed. By this means, high-risk patients can be defined; they are the candidates for clinical trials mandatory for treatment development. The metastatic process as well as the reaction to chemotherapy depends on the biological make-up of the tumor. Current chemotherapy regimens do not improve the survival rates of patients with metastatic disease, due to resistance mechanisms of tumor cells. New drugs with direct access to the cell death machinery in tumor cells might contribute to more effective treatment of STS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 52(1): 23–47, 2001

    Google Scholar 

  2. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, Vilain MO, Jacquemier J, Duplay H, Sastre X, Barlier C, Henry-Amar M, Mace-Lesech J, Contesso G: Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14(3): 869–877, 1996

    Google Scholar 

  3. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF: Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 218(6): 705–712, 1993

    Google Scholar 

  4. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, Sastre X, Vilain MO, Bonichon F, N'Guyen BB: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 91(10): 1914–1926, 2001

    Google Scholar 

  5. Weingrad DN, Rosenberg SA: Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery 84(2): 231–240, 1978

    Google Scholar 

  6. Mazeron JJ, Suit HD: Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 60(8): 1800–1808, 1987

    Google Scholar 

  7. Lawrence W, Jr., Hays DM, Heyn R, Tefft M, Crist W, Beltangady M, Newton W, Jr., Wharam M: Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 60(4): 910–915, 1987

    Google Scholar 

  8. Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, Klepp R, Moller TR, Rydholm A, Saeter G, Wahlstrom O, Wiklund T: Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 72(2): 150–159, 2001

    Google Scholar 

  9. Nijhuis PH, Schaapveld M, Otter R, Molenaar WM, van der Graaf WT, Hoekstra HJ: Epidemiological aspects of soft tissue sarcomas (STS) – consequences for the design of clinical STS trials. Eur J Cancer 35(12): 1705–1710, 1999

    Google Scholar 

  10. Sastre-Garau X, Coindre JM, Leroyer A, Terrier P, Ollivier L, Stockle E, Bonichon F, Collin F, Le Doussal V, Contesso G, Vilain MO, Jacquemier J, Nguyen BB: Predictive factors for complete removal in soft tissue sarcomas: A retrospective analysis in a series of 592 cases. J Surg Oncol 65(3): 175–182, 1997

    Google Scholar 

  11. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14(5): 1679–1689, 1996

    Google Scholar 

  12. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF: Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235(3): 424–434, 2002

    Google Scholar 

  13. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350(9092): 1647–1654, 1997

    Google Scholar 

  14. Weiss SW, Goldblum JR: Enzinger and Weiss's soft tissue tumors, 4th edn, Mosby, St. Louis, 2001

    Google Scholar 

  15. Chan HS, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8(4): 689–704, 1990

    Google Scholar 

  16. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL: MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 18(14): 2685–2694, 2000

    Google Scholar 

  17. Bunting KD, Townsend AJ: De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J Biol Chem 271(20): 11884–11890, 1996

    Google Scholar 

  18. Fleming RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17(5 Pt 2): 146S–154S, 1997

    Google Scholar 

  19. Richardson ME, Siemann DW: Tumor cell heterogeneity: Impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 39(4): 789–795, 1997

    Google Scholar 

  20. Sladek NE: Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 5(8): 607–625, 1999

    Google Scholar 

  21. Colvin OM: Drug resistance in the treatment of sarcomas. Semin Oncol 24(5): 580–591, 1997

    Google Scholar 

  22. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, Demoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R: The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196(3): 305–315, 1982

    Google Scholar 

  23. Leibel SA, Tranbaugh RF, Wara WM, Beckstead JH, Bovill EG, Phillips TL: Soft tissue sarcomas of the extremities: Survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer 50(6): 1076–1083, 1982

    Google Scholar 

  24. Shiu MH, Castro EB, Hajdu SI, Fortner JG: Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg 182(5): 597–602, 1975

    Google Scholar 

  25. Ramanathan RC, A'Hern R, Fisher C, Thomas JM: Prognostic index for extremity soft tissue sarcomas with isolated local recurrence. Ann Surg Oncol 8(4): 278–289, 2001

    Google Scholar 

  26. Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, Gustafson P, Saeter G, Walloe A: Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 36(6): 710–716, 2000

    Google Scholar 

  27. McKee MD, Liu DF, Driscoll D, Brooks J, Gibbs JF, Kraybill W: Margin width has prognostic significance for extremity/truncal sarcoma. SSO 54th Annual Cancer Symposium, 2001 (Abstract)

  28. Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF: Effect of reresection in extremity soft tissue sarcoma. Ann Surg 231(5): 655–663, 2000

    Google Scholar 

  29. Shiu MH, Hilaris BS, Harrison LB, Brennan MF: Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 21(6): 1485–1492, 1991

    Google Scholar 

  30. Markhede G, Angervall L, Stener B: A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 49(8): 1721–1733, 1982

    Google Scholar 

  31. Collin C, Godbold J, Hajdu S, Brennan M: Localized extremity soft tissue sarcoma: An analysis of factors affecting survival. J Clin Oncol 5(4): 601–612, 1987

    Google Scholar 

  32. Rooser B, Attewell R, Berg NO, Rydholm A: Survival in soft tissue sarcoma. Prognostic variables identified by multivariate analysis. Acta Orthop Scand 58(5): 516–522, 1987

    Google Scholar 

  33. Emrich LJ, Ruka W, Driscoll DL, Karakousis CP: The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas. J Clin Epidemiol 42(2): 105–110, 1989

    Google Scholar 

  34. Stotter AT, A'Hern RP, Fisher C, Mott AF, Fallowfield ME, Westbury G: The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 65(5): 1119–1129, 1990

    Google Scholar 

  35. Rooser B, Gustafson P, Rydholm A: Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer 65(8): 1727–1729, 1990

    Google Scholar 

  36. Gustafson P, Rooser B, Rydholm A: Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 67(8): 2083–2086, 1991

    Google Scholar 

  37. Singer S, Antman K, Corson JM, Eberlein TJ: Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 127(5): 548–553, 1992

    Google Scholar 

  38. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ: Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 219(2): 165–173, 1994

    Google Scholar 

  39. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF: Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 15(2): 646–652, 1997

    Google Scholar 

  40. Ueda T, Yoshikawa H, Mori S, Araki N, Myoui A, Kuratsu S, Uchida A: Influence of local recurrence on the prognosis of soft-tissue sarcomas. J Bone Joint Surg Br 79(4): 553–557, 1997

    Google Scholar 

  41. Komdeur R, Plaat BEC, Hoekstra HJ, Molenaar WM, Hollema H, van den Berg E, Mastik MF, van der Graaf WTA: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 91(10): 1940–1948, 2001

    Google Scholar 

  42. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF: Pulmonary metastases from soft tissue sarcoma: Analysis of patterns of diseases and postmetastasis survival. Ann Surg 229(5): 602–610, 1999

    Google Scholar 

  43. Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ: Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 40(4): 807–814, 1998

    Google Scholar 

  44. Van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, Nielsen OS, Boudinet A, Tursz T, Schmitz PI: Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Study of 255 patients. Cancer 77(4): 675–682, 1996

    Google Scholar 

  45. Van Geel AN, Hoekstra HJ, van Coevorden F, Meyer S, Bruggink ED, Blankensteijn JD: Repeated resection of recurrent pulmonary metastatic soft tissue sarcoma. Eur J Surg Oncol 20(4): 436–440, 1994

    Google Scholar 

  46. Weiser MR, Downey RJ, Leung DH, Brennan MF: Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 191(2): 184–190, 2000

    Google Scholar 

  47. Burt ME, Liu D, Abolhoda A, Ross HM, Kaneda Y, Jara E, Casper ES, Ginsberg RJ, Brennan MF: Isolated lung perfusion for patients with unresectable metastases from sarcoma: A phase I trial. Ann Thorac Surg 69(5): 1542–1549, 2000

    Google Scholar 

  48. Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA: Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 2(2): 151–155, 1998

    Google Scholar 

  49. Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blumgart LH, Fong Y: Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients. Surgery 121(6): 625–632, 1997

    Google Scholar 

  50. Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 30(10): 1213–1220, 1999

    Google Scholar 

  51. Wilson AN, Davis A, Bell RS, O'sullivan B, Catton C, Madadi F, Kandel R, Fornasier VL: Local control of soft tissue sarcoma of the extremity: The experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 30A(6): 746–751, 1994

    Google Scholar 

  52. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1): 197–203, 1998

    Google Scholar 

  53. Alektiar KM, Leung D, Zelefsky MJ, Healey JH, Brennan MF: Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 9(1): 48–56, 2002

    Google Scholar 

  54. Pisters PW: Combined modality treatment of extremity soft tissue sarcomas. Ann Surg Oncol 5(5): 464–472, 1998

    Google Scholar 

  55. Hoffmann W, Kortmann RD, Bamberg M: Radiotherapy in the treatment of metastases of soft tissue sarcomas. Recent Results Cancer Res 138: 117–121, 1995

    Google Scholar 

  56. Keohan ML, Taub RN: Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin Oncol 24(5): 572–579, 1997

    Google Scholar 

  57. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 19(5): 1238–1247, 2001

    Google Scholar 

  58. Sawyer M, Bramwell V: The treatment of distant metastases in soft tissue sarcoma. Semin Radiat Oncol 9(4): 389–400, 1999

    Google Scholar 

  59. Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 9(4): 765–785, 1995

    Google Scholar 

  60. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17(1): 150–157, 1999

    Google Scholar 

  61. Sarlomo–Rikala M, Kovatich AJ, Barusevicius A, Miettinen M: CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11(8): 728–734, 1998

    Google Scholar 

  62. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF: Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: A clinical comparison. Ann Surg Oncol 8(4): 290–299, 2001

    Google Scholar 

  63. Fletcher CD, Gustafson P, Rydholm A, Willén H, Åkerman M: Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of sub-classification. J Clin Oncol 19(12): 3045–3050, 2001

    Google Scholar 

  64. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M, Hajdu SI, Brennan MF: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 10(8): 1317–1329, 1992

    Google Scholar 

  65. La Quaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S, Brennan MF: The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 73(1): 109–117, 1994

    Google Scholar 

  66. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato DP, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358(9291): 1421–1423, 2001

    Google Scholar 

  67. Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisenberg B, Heinrich MC, Druker BJ, Tuveson D, Dimitrijevic S, Silberman S and Demetri GD: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Proc ASCO 2001 (Abstract)

  68. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14): 1052–1056, 2001

    Google Scholar 

  69. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS: Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73(10): 2506–2511, 1994

    Google Scholar 

  70. Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, Bodaert A, De Mascarel I, De Mascarel A, Goussot JF: Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58(2): 306–309, 1986

    Google Scholar 

  71. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, De Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C: Soft-tissue sarcomas of adults: Study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33(1): 37–42, 1984

    Google Scholar 

  72. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15(1): 350–362, 1997

    Google Scholar 

  73. Kandel RA, Bell RS, Wunder JS, O'sullivan B, Catton CN, White LM, Davis AM: Comparison between a 2-and 3-grade system in predicting metastatic-free survival in extremity soft-tissue sarcoma. J Surg Oncol 72(2): 77–82, 1999

    Google Scholar 

  74. Hashimoto H, Daimaru Y, Takeshita S, Tsuneyoshi M, Enjoji M: Prognostic significance of histologic parameters of soft tissue sarcomas. Cancer 70(12): 2816–2822, 1992

    Google Scholar 

  75. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of soft tissue sarcoma. Virchows Arch 434(3): 187–191, 1999

    Google Scholar 

  76. Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, Gunterberg B, Kindblom LG: Synovial sarcoma: Identification of low and high risk groups. Cancer 85(12): 2596–2607, 1999

    Google Scholar 

  77. Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, Fiche M, Collin F, Vilain MO, Bertrand G, Jacquemier J, Sastre-Garau X, Bui NB, Bonichon F, Coindre JM: Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J Clin Oncol 19(2): 525–534, 2001

    Google Scholar 

  78. Fleming JB, Berman RS, Cheng SC, Chen NP, Hunt KK, Feig BW, Respondek PM, Yasko AW, Pollack A, Patel SR, Burgess MA, Papadopoulos NE, Plager C, Zagars G, Benjamin RS, Pollock RE, Pisters PW: Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 17(9): 2772–2780, 1999

    Google Scholar 

  79. Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI, Brennan MF: Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 134(2): 190–194, 1999

    Google Scholar 

  80. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14(3): 859–868, 1996

    Google Scholar 

  81. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85(2): 389–395, 1999

    Google Scholar 

  82. Torosian MH, Friedrich C, Godbold J, Hajdu SI, Brennan MF: Soft-tissue sarcoma: Initial characteristics and prognostic factors in patients with and without metastatic disease. Semin Surg Oncol 4(1): 13–19, 1988

    Google Scholar 

  83. Linehan DC, Lewis JJ, Leung D, Brennan MF: Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 18(8): 1637–1643, 2000

    Google Scholar 

  84. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H: Pretreatment TNM staging of childhood rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer 80(6): 1165–1170, 1997

    Google Scholar 

  85. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, et al.: AJCC Cancer Staging Manual, 5th edn, Lippincott, Philadelphia, 1997

    Google Scholar 

  86. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop (153): 106–120, 1980

    Google Scholar 

  87. Wunder JS, Healey JH, Davis AM, Brennan MF: A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 88(12): 2721–2730, 2000

    Google Scholar 

  88. Hajdu SI, Shiu MH, Brennan MF: The role of the pathologist in the management of soft tissue sarcomas. World J Surg 12(3): 326–331, 1988

    Google Scholar 

  89. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91(19): 1647–1653, 1999

    Google Scholar 

  90. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM: P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 5(9): 1452–1460, 1987

    Google Scholar 

  91. Plaat BEC, van der Graaf WTA, Hollema H, Hoekstra HJ, van den Berg E, Mastik MF, Molenaar WM: Expression of the multidrug resistance associated proteins P-gp, MRP1 and LRP in Soft Tissue Sarcomas. CTOS 1999 (Abstract)

  92. Borst P, Schinkel AH: Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13(6): 217–222, 1997

    Google Scholar 

  93. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92(16): 1295–1302, 2000

    Google Scholar 

  94. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65(2): 230–237, 1996

    Google Scholar 

  95. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB: Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 9(9): 3808–3820, 1989

    Google Scholar 

  96. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1): 152–162, 1976

    Google Scholar 

  97. Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB, Das Gupta TK: Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 15(10): 3249–3257, 1997

    Google Scholar 

  98. Nakanishi H, Myoui A, Ochi T, Aozasa K: P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 123(6): 352–356, 1997

    Google Scholar 

  99. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR: Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer 36(7): 881–888, 2000

    Google Scholar 

  100. Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, Lucas DR: Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 86(6): 976–981, 1999

    Google Scholar 

  101. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M: Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 102(1): 61–67, 1994

    Google Scholar 

  102. Wexler LH, Helman LJ: Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG (eds) Principles and Practice of Pediatric Oncology, 3rd edn, Lippincott-Raven, Philadelphia, 1997, pp. 799–829

    Google Scholar 

  103. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13(3): 610–630, 1995

    Google Scholar 

  104. Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ: P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14(3): 886–900, 1996

    Google Scholar 

  105. Dirven HA, Megens L, Oudshoorn MJ, Dingemanse MA, van Ommen B, van Bladeren PJ: Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol 8(7): 979–986, 1995

    Google Scholar 

  106. Mulders TM, Keizer, Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ: Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin Cancer Res 1(12): 1525–1536, 1995

    Google Scholar 

  107. Boven E, Pinedo HM, van Hattum AH, Scheffer PG, Peters WH, Erkelens CA, Schluper HM, Kuiper CM, Ark-Otte J, Giaccone G: Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. Br J Cancer 78(12): 1586–1593, 1998

    Google Scholar 

  108. Nagata S: Apoptosis by death factor. Cell 88(3): 355–365, 1997

    Google Scholar 

  109. Eggermont AM, Schraffordt Koops H, Klausner JM, Schlag PM, Lienard D, Kroon BBR, Gustafson P, Steinmann G, Clarke J, Lejeune FJ: Limb salvage by Isolated Limb Perfusion (ILP) with TNF and Melphalan in patients with locally advanced soft tissue sarcomas: Outcome of 270 ILPs in 246 patients. Proc. ASCO 18, 535a. 1999 (Abstract)

    Google Scholar 

  110. ten Hagen TL, Van Der Veen AH, Nooijen PT, van Tiel ST, Seynhaeve AL, Eggermont AM: Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 87(6): 829–837, 2000

    Google Scholar 

  111. Walther W, Stein U: Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: Increased cyto-toxicity of MDR relevant drugs. J Cancer Res Clin Oncol 120(8): 471–478, 1994

    Google Scholar 

  112. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH: Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 89(11): 807–813, 1997

    Google Scholar 

  113. ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM: Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic anti-tumor activity after systemic administration in combination with liposomal doxorubicin (Doxil(R)) in soft tissue sarcoma-bearing rats. Int J Cancer 97(1): 115–120, 2002

    Google Scholar 

  114. Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG: Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 12(17): 2035–2049, 2001

    Google Scholar 

  115. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L: Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182(5): 1223–1230, 1995

    Google Scholar 

  116. Timmer T, de Vries EG, de Jong S: Fas receptor-mediated apoptosis: A clinical application? J Pathol 196(2): 125–134, 2002

    Google Scholar 

  117. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61(2): 577–581, 2001

    Google Scholar 

  118. de Vries EG, van der Graaf WT, Heijenbrok FJ, Hoekstra HJ, de Jong S: Don't blaze the trailblazer TRAIL too early. Lancet 356(9246): 2014, 2000

    Google Scholar 

  119. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA: Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6(10): 4119–4127, 2000

    Google Scholar 

  120. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22): 8118–8121, 2001

    Google Scholar 

  121. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59(17): 4297–4300, 1999

    Google Scholar 

  122. Torihashi S, Horisawa M, Watanabe Y: c-Kit immunoreactive interstitial cells in the human gastrointestinal tract. J Auton Nerv Syst 75(1): 38–50, 1999

    Google Scholar 

  123. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U: Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 61(5): 2200–2206, 2001

    Google Scholar 

  124. Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio N, Horenstein AL, Pistamiglio P, Vai S, Berger M, di Montezemolo LC, Madon E, Basso G: c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91(7): 2397–2405, 1998

    Google Scholar 

  125. Plaat E, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den BE, Scheper RJ, van der Graaf WT: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18(18): 3211–3220, 2000

    Google Scholar 

  126. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20(36): 5054–5058, 2001

    Google Scholar 

  127. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92(7): 2558–2562, 1995

    Google Scholar 

  128. Franklin WA, Christison WH, Colley M, Montag AG, Stephens JK, Hart CE: In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res 50(19): 6344–6348, 1990

    Google Scholar 

  129. Palman C, Bowen-Pope DF, Brooks JJ: Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 66(1): 108–115, 1992

    Google Scholar 

  130. Wang J, Coltrera MD, Gown AM: Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: An immunohistochemical and in situ hybridization study. Cancer Res 54(2): 560–564, 1994

    Google Scholar 

  131. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61(15): 5778–5783, 2001

    Google Scholar 

  132. Trent JC, Hannay J, Li L, Patel S, Benjamin RS, Pollock RE, Yu DH: Inhibition of PDGF receptor tyrosine kinases by STI-571 in human soft-tissue sarcoma. Sarcoma 5(Suppl 1): 10–11, 2001

    Google Scholar 

  133. Hashimoto M, Ohsawa M, Ohnishi A, Naka N, Hirota S, Kitamura Y, Aozasa K: Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest 73(6): 859–863, 1995

    Google Scholar 

  134. Bridge JA, Liu J, Weibolt V, Baker KS, Perry D, Kruger R, Qualman S, Barr F, Sorensen P, Triche T, Suijkerbuijk R: Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: An intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 27(4): 337–344, 2000

    Google Scholar 

  135. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4(5): 619–622, 1998

    Google Scholar 

  136. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, Zimmer A, Muller U, Samson E, Quintanilla-Martinez L, Zimmer A: Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275(37): 28341–28344, 2000

    Google Scholar 

  137. Storz P, Doppler H, Horn-Muller J, Muller G, Pfizenmaier K: TNF down-regulation of receptor tyrosine kinase-dependent mitogenic signal pathways as an important step in cytostasis induction and commitment to apoptosis of Kym-1 rhabdomyosarcoma cells. Cell Death Differ 7(10): 955–965, 2000

    Google Scholar 

  138. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Res 59(15): 3588–3591, 1999

    Google Scholar 

  139. Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M: The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer 72(2): 478–485, 1993

    Google Scholar 

  140. Skytting BT, Bauer HC, Perfekt R, Nilsson G, Larsson O: Ki-67 is strongly prognostic in synovial sarcoma: Analysis based on 86 patients from the Scandinavian Sarcoma group register. Br J Cancer 80(11): 1809–1814, 1999

    Google Scholar 

  141. Kawauchi S, Fukuda T, Oda Y, Saito T, Oga A, Takeshita M, Yokoyama K, Chuman H, Iwamoto Y, Sasaki K, Tsuneyoshi M: Prognostic significance of apoptosis in synovial sarcoma: Correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins. Mod Pathol 13(7): 755–765, 2000

    Google Scholar 

  142. Kawauchi S, Goto Y, Liu XP, Furuya T, Oga A, Oda Y, Tsuneyoshi M, Ihara K, Sasaki K: Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma. Cancer 91(5): 1005–1012, 2001

    Google Scholar 

  143. DeGiovanni C, Melani C, Nanni P, Landuzzi L, Nicoletti G, Frabetti F, Griffoni C, Colombo MP, Lollini PL: Redundancy of autocrine loops in human rhabdomyosarcoma cells: Induction of differentiation by suramin. Br J Cancer 72(5): 1224–1229, 1995

    Google Scholar 

  144. Ricci C, Landuzzi L, Rossi I, De Giovanni C, Nicoletti G, Astolfi A, Pupa S, Menard S, Scotlandi K, Nanni P, Lollini PL: Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer 87(1): 29–36, 2000

    Google Scholar 

  145. Merlino G, Helman LJ: Rhabdomyosarcoma–working out the pathways. Oncogene 18(38): 5340–5348, 1999

    Google Scholar 

  146. Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25(1): 1–6, 2000

    Google Scholar 

  147. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ: A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 38(1–2): 1–11, 2000

    Google Scholar 

  148. Johnstone RW, Cretney E, Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93(3): 1075–1085, 1999

    Google Scholar 

  149. Lehne G, De Angelis P, den Boer M, Rugstad HE: Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 13(5): 768–778, 1999

    Google Scholar 

  150. Ruth AC, Roninson IB: Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 60(10): 2576–2578, 2000

    Google Scholar 

  151. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95(12): 7024–7029, 1998

    Google Scholar 

  152. Kim CH, Gollapudi S, Park J, Lee T, Kim Y, Gupta S: Impairment of Fas-mediated apoptosis in multidrug resistance. Proc AACR 41, 842. 2000 (Abstract)

    Google Scholar 

  153. Cullen K, Davey R, Davey M: The drug resistance proteins, multidrug resistance-associated protein and Pglycoprotein, do not confer resistance to Fas-induced cell death. Cytometry 43(3): 189–194, 2001

    Google Scholar 

  154. Hoffman MM, Wei LY, Roepe PD: Are altered pHi and membrane potential in huMDR1 transfectants sufficient to cause MDR protein-mediated multidrug resistance? J Gen Physiol 108(4): 295–313, 1996

    Google Scholar 

  155. Gottlieb RA, Nordberg J, Skowronski E, Babior BM: Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA 93(2): 654–658, 1996

    Google Scholar 

  156. Pallis M, Russell N: P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95(9): 2897–2904, 2000

    Google Scholar 

  157. Peaston AE, Gardaneh M, Franco AV, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB, Marshall GM: MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 85(10): 1564–1571, 2001

    Google Scholar 

  158. Aszalos A, Ladanyi A, Bocsi J, Szende B: Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators. Cancer Lett 167(2): 157–162, 2001

    Google Scholar 

  159. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD: Safety and efficacy of the multidrug-resistance inhibitor Biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 8(2): 383–393, 2002

    Google Scholar 

  160. Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38: 543–549, 2002

    Google Scholar 

  161. Kerbel RS, Kobayashi H, Graham CH: Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? J Cell Biochem 56(1): 37–47, 1994

    Google Scholar 

  162. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51(10): 2720–2726, 1991

    Google Scholar 

  163. Bashir I, Sikora K, Foster CS: Multidrug resistance and behavioural phenotype of cancer cells. Cell Biol Int 17(10): 907–917, 1993

    Google Scholar 

  164. Staroselsky AN, Mahlin T, Savion N, Klein O, Nordenberg J, Donin N, Michowitz M, Leibovici J: Metastatic potential and multidrug resistance correlation in the B16 melanoma system. J Exp Ther Oncol 1(4): 251–259, 1996

    Google Scholar 

  165. Nokihara H, Yano S, Nishioka Y, Hanibuchi M, Higasida T, Tsuruo T, Sone S: A new quinoline derivative ms-209 reverses multidrug resistance and inhibits multiorgan metastases by p-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res 92(7): 785–792, 2001

    Google Scholar 

  166. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al Mehdi AB, Bernhard EJ, Muschel RJ: Apoptosis: An early event in metastatic inefficiency. Cancer Res 61(1): 333–338, 2001

    Google Scholar 

  167. Kim WH, Schnaper HW, Nomizu M, Yamada Y, Kleinman HK: Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin. Cancer Res 54(18): 5005–5010, 1994

    Google Scholar 

  168. Farias EF, Aguirre Ghiso JA, Ladeda V, Bal de Kier JE: Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. Int J Cancer 78(6): 727–734, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Komdeur, R., Hoekstra, H.J., van den Berg, E. et al. Metastasis in Soft Tissue Sarcomas: Prognostic Criteria and Treatment Perspectives. Cancer Metastasis Rev 21, 167–183 (2002). https://doi.org/10.1023/A:1020893200768

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020893200768

Navigation